GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Neurocrine Biosciences Inc (BSP:N1BI34) » Definitions » Short-Term Debt

Neurocrine Biosciences (BSP:N1BI34) Short-Term Debt : R$0 Mil (As of Mar. 2025)


View and export this data going back to 2020. Start your Free Trial

What is Neurocrine Biosciences Short-Term Debt?

Neurocrine Biosciences's Short-Term Debt for the quarter that ended in Mar. 2025 was R$0 Mil.

Neurocrine Biosciences's annual Short-Term Debt declined from Dec. 2022 (R$889 Mil) to Dec. 2023 (R$833 Mil) and declined from Dec. 2023 (R$833 Mil) to Dec. 2024 (R$0 Mil).


Neurocrine Biosciences Short-Term Debt Historical Data

The historical data trend for Neurocrine Biosciences's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Neurocrine Biosciences Short-Term Debt Chart

Neurocrine Biosciences Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Short-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 888.57 833.46 -

Neurocrine Biosciences Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,289.77 - - - -

Neurocrine Biosciences Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.


Neurocrine Biosciences Short-Term Debt Related Terms

Thank you for viewing the detailed overview of Neurocrine Biosciences's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


Neurocrine Biosciences Business Description

Traded in Other Exchanges
Address
6027 Edgewood Bend Court, San Diego, CA, USA, 92130
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.

Neurocrine Biosciences Headlines

No Headlines